Ionis Pharmaceuticals Inc (IONS) : Sonora Investment Management scooped up 645 additional shares in Ionis Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 15, 2016. The investment management firm now holds a total of 123,568 shares of Ionis Pharmaceuticals Inc which is valued at $3,421,598.Ionis Pharmaceuticals Inc makes up approximately 1.89% of Sonora Investment Management’s portfolio.
Other Hedge Funds, Including , Gofen Glossberg Il sold out all of its stake in IONS during the most recent quarter. The investment firm sold 6,760 shares of IONS which is valued $166,837.Davenport Co boosted its stake in IONS in the latest quarter, The investment management firm added 200 additional shares and now holds a total of 28,760 shares of Ionis Pharmaceuticals Inc which is valued at $709,797. Ionis Pharmaceuticals Inc makes up approx 0.01% of Davenport Co’s portfolio.
On the company’s financial health, Ionis Pharmaceuticals Inc reported $-0.52 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 4, 2016. Analyst had a consensus of $-0.54. The company had revenue of $36.90 million for the quarter, compared to analysts expectations of $36.21 million. The company’s revenue was down -41.1 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.14 EPS.
Many Wall Street Analysts have commented on Ionis Pharmaceuticals Inc. Shares were Reiterated by Needham on May 27, 2016 to “Buy” and Lowered the Price Target to $ 55 from a previous price target of $88 .
Ionis Pharmaceuticals Inc. formerly Isis Pharmaceuticals Inc. is a ribonucleic acid-targeted (RNA-targeted) drug discovery and development company. The Company is focused on discovering and developing antisense drugs. Its antisense drugs are used to treat a range of diseases including cardiovascular; metabolic; severe and rare diseases including neurological disorders and cancer. Volanesorsen is a drug indicated to treat patients with high triglyceride levels including patients with a genetic condition called familial chylomicronemia syndrome (FCS) and patients with partial lipodystrophy. It is focused on bringing its late-stage Phase III drugs nusinersen volanesorsen and IONIS-TTR to the market. Its lipid-lowering product KYNAMRO (mipomersen sodium) injection is on the market in the United States for patients with homozygous familial hypercholesterolemia (HoFH). Its products also include Alicaforsen IONIS-DMPK-2.5 Plazomicin and IONIS-GCGR.